NCT04440891

Brief Summary

This is a randomized sham control study to evaluate how repetitive Transcranial Magnetic Stimulation (rTMS), interactive cognitive training, or the combination of rTMS and cognitive training reduce the cognitive decline of patients diagnosed with Alzheimer's disease

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 3, 2019

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 22, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 22, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 2, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2021

Completed
Last Updated

August 14, 2023

Status Verified

August 1, 2023

Enrollment Period

2.1 years

First QC Date

May 22, 2020

Last Update Submit

August 7, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cognitive Performance

    Change in cognitive task performance over time using the total score on the Mini Mental State Examination (range 0-30)

    6 months after completion study procedure

Secondary Outcomes (2)

  • Brain MRI

    6 months after completion of study procedure compared to screening

  • Memory Performance

    6 months after completion of study procedure compared to screening

Study Arms (4)

TMS-Stimulation with X-Torp task

EXPERIMENTAL

TMS with VR 1 experimental arm

Device: TMS stimulation with X-Torp task

TMS-Stimulation with MindMotion Go

EXPERIMENTAL

TMS with VR 2 experimental arm

Device: TMS-Stimulation with MindMotion Go

TMS-Sham with X-Torp task

SHAM COMPARATOR

TMS sham control with VR 1

Device: TMS-Sham with X-Torp task

TMS-Sham with MindMotion Go

SHAM COMPARATOR

TMS sham control with sham VR 2

Device: TMS-Sham with MindMotion Go

Interventions

TMS-Stimulation with X-Torp task

TMS-Stimulation with X-Torp task

TMS-Stimulation with MindMotion Go

TMS-Stimulation with MindMotion Go

TMS-Sham with X-Torp task

TMS-Sham with X-Torp task

TMS-Sham with MindMotion Go

TMS-Sham with MindMotion Go

Eligibility Criteria

Age50 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or Female between 50-85 years of age
  • Able and willing to give informed consent
  • Probable AD consistent with NIA/AA criteria
  • Modified Hachinski Ischemia Scale (MHIS) score of \<= 4
  • Geriatric Depression Scale (GDS) score of \<= 6
  • Mini Mental State Exam (MMSE) score 18-26. The MMSE adjusted scoring instructions may be followed for screening patients as applicable.

You may not qualify if:

  • Unstable medical conditions
  • Visual impairments
  • Mobility limitations
  • Cognition-enhancing medication unless on a stable dosage for at least 3 months before the start of the trial.
  • History of epilepsy or seizure disorder
  • History of psychosis
  • Current thoughts of suicidal ideation or self-harm as assessed by the Columbia-Suicide severity rating scale score
  • Progressive neurological disorder or focal signs of abnormality on neurological exam as conducted by a neurologist (other than current diagnosis of AD)
  • Tinnitus
  • Metal implants (excluding dental fillings)
  • Possible pregnancy
  • Substance use disorder within the past six months
  • Have other mental or physical conditions that are inappropriate for study participation at PI's or delegated sub investigator's discretion.
  • Intake of one or a combination of the drugs that may due to their significant seizure threshold lowering potential

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West Virginia University Rockefeller Neuroscience Institute

Morgantown, West Virginia, 26506, United States

Location

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Marc Haut, PhD

    Rockefeller Neuroscience Institute

    STUDY CHAIR
  • Victor Finomore, PhD

    Rockefeller Neuroscience Institute

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

May 22, 2020

First Posted

June 22, 2020

Study Start

October 3, 2019

Primary Completion

November 2, 2021

Study Completion

November 2, 2021

Last Updated

August 14, 2023

Record last verified: 2023-08

Locations